Sanofi SA (NAS:SNY)
$ 48.69 0.6274 (1.31%) Market Cap: 121.69 Bil Enterprise Value: 132.17 Bil PE Ratio: 20.85 PB Ratio: 1.53 GF Score: 84/100

Sanofi SA Nirsevimab R&D Investor Event Transcript

Jul 30, 2020 / 03:00PM GMT
Release Date Price: $52.5 (-0.64%)
Eva Schaefer;Jansen
Sanofi - IR Officer

Good afternoon, and good evening to Asia. I'm Eva Schaefer-Jansen of Sanofi Investor Relations. Welcome to this event. This is the fifth in a series of 5 R&D events, highlighting the accelerating pipeline momentum building within Sanofi R&D.

Today, we will focus on the Phase IIb results of nirsevimab just published in the New England Journal of Medicine. As usual, you can find the slides to this call on the Investors page of our website at sanofi.com. Next slide, please.

So I would like to remind you that information presented during this event contain forward-looking statements that involve known and unknown risks, uncertainties and other factors that may cause actual results to differ materially. I refer you to our Form 20-F document on file with the SEC and also our Document dâEnregistrement Universel for a description of these factors. Next slide, please.

So I would like to introduce you to our speakers today. We have here Thomas Triomphe, Global Head of Sanofi Pasteur; we have Su-Peing Ng, Global Head of

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot